Supply of products by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring that these goods are safe, of high quality, and meet necessary standards. The Act was introduced to address the need for a comprehensive legislative framework governing the approval, advertising, and monitoring of therapeutic goods, thereby protecting public health by ensuring that only safe and effective products are available. The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia, with the aim of establishing a robust regulatory system for therapeutic goods, ensuring that they meet safety, quality, and efficacy standards before being made available to the public. The policy objective of the Act is to safeguard public health by regulating the supply and use of therapeutic goods, thereby preventing harm and ensuring that consumers have access to safe and effective products.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods in Australia, with Section 14 and 14A addressing specific notices concerning the supply of certain therapeutic goods. In this instance, the Act applies to Merck Sharp & Dohme Australia Pty Ltd, a company based in North Ryde, NSW, and pertains to the supply of three specific products: the M-M-R II composite pack with diluent vial, the M-M-R II injection vial, and the M-M-R II composite pack with diluent syringe. The Act applies to these products' labelling requirements, specifically permitting deviations from certain clauses in the Therapeutic Goods Order No 69. The exemption allows the omission of the names and quantities of active ingredients from the vial labels, subject to conditions set by the delegate of the Secretary of the Department of Health and Ageing. The Act's jurisdictional reach is national, as it is a Commonwealth Act, and its application is limited to the products and labelling specifications outlined in the notice. The Act does not extend or restrict its application through subordinate instruments in this specific context.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) contains several key sections that govern the supply and labelling of therapeutic goods in Australia. Specifically, sections 14 and 14A provide the framework for the Secretary of the Department of Health and Ageing to grant consent for the supply of certain therapeutic goods that do not fully comply with the Therapeutic Goods Order No 69. In this instance, the delegate of the Secretary has given consent for Merck Sharp & Dohme Australia Pty Ltd to supply specific M-M-R II products, which include Aust R 118449, Aust R 118451, and Aust R 201877, and to allow these products to not conform to the labelling requirements specified in clauses 3(2)(b) and 3(2)(c) of the Therapeutic Goods Order No 69. The obligations imposed by the Act require Merck Sharp & Dohme Australia Pty Ltd to ensure that the specified M-M-R II products are supplied in accordance with the conditions set out by the delegate of the Secretary. This includes maintaining the integrity of the products as originally consented to and not making any changes to the products listed. The consent granted by the delegate of the Secretary is conditional upon these obligations being met. The company must adhere strictly to the terms under which the consent was given, particularly in relation to the products' specifications and labelling. Failure to comply with the conditions set out in the consent, or any other relevant provisions of the Act, may result in legal consequences. The Therapeutic Goods Act 1989 provides for various offences and penalties for breaches. The specific consequences for non-compliance are not detailed in the provided extract, but generally, breaches of the Act can lead to criminal charges, fines, and other civil remedies. The maximum penalties for breaches of the Act can be substantial and may vary depending on the nature and severity of the offence. It is essential for Merck Sharp & Dohme Australia Pty Ltd to be fully aware of and comply with these obligations to avoid potential legal repercussions.